The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety,
tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and
biomarkers of ES104 in patients with unresectable locally advanced or metastatic colorectal
cancer who have failed systemic therapies.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.